ArticleEmerging microbes & infections2026
Tick-borne encephalitis in the Åland Islands, Finland: incidence and disease course since the implementation of a general TBE vaccination programme.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis (TBE) is a potentially life-threatening viral disease with rising incidence in Europe. This retrospective study investigates the incidence, clinical course, and long-term outcome of TBE in Åland, a region endemic for the disease, following the introduction of a TBE vaccination programme in 2006. All patients diagnosed with TBE in Åland between 2006 and 2023, in accordance with the diagnostic criteria established by the European Centre for Disease Prevention and Control (ECDC), were included in the study. A review of medical records was conducted, and epidemiological and laboratory data were systematically collected. Disease severity and clinical outcome were assessed. TBE was diagnosed in 145 patients (66% male; median age 53 years; 10% children <18 years). The median TBE incidence was 29/100,000/year. Primary care was the first point of contact in 48% of cases. Of all patients, 72 (50%) were unvaccinated, 46 (32%) incompletely vaccinated and 20 (14%) completely vaccinated. Fifty-seven (39%) were diagnosed with meningitis and 88 (61%) with meningoencephalitis. Overall, 117/145 (81%) patients were hospitalized and 13/145 (9%) required intensive care. Severity of disease correlated with increasing age. Two fatalities occurred. Unlike neighbouring regions, Åland did not experience an increase in TBE incidence, likely due to the implementation of the vaccination programme. Most disease courses were monophasic and occurred in unvaccinated individuals. Surprisingly, a significant number of breakthrough infections were observed, particularly among those with incomplete vaccination, who more frequently developed severe disease. However, at two-year follow-up, 86% of patients were considered clinically recovered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.